Our Location
Email Us
Phone Us
Clinical Use
Bovine Haemoglobin supplied as an intravenous infusion can deliver significant therapeutic levels of oxygen to support ischaemic organs following stroke, MI, trauma and acute resuscitation. It has been used to support fulminating haemolytic anaemias and other critical illnesses. It has also been used in solid organ transplantation to improve donor organ viability by supplying oxygen to the donor organ before transplantation.
Veterinary
Bovine Haemoglobin has been successfully & safely used in @ 300,000 treatment episodes in dogs, cats, large animals and exotic species.
It was approved for veterinary usage in 1998 and remains on the veterinary index in the US.
Investors
The original inventor of Bovine haemoglobin products has reinvented the manufacturing process with single use technology and novel chromatography techniques. A new manufacturing plant nears completion in the US with a further plant planned for the UK. Together with a UK based team of experienced clinical developers and clinical trials specialists, Bovine Haemoglobin will be relaunched in the UK and US shortly for veterinary and human usage.
Matinicus Pharma is a biotech company founded by experienced Bioengineers 25+ year experience in scaled-up of ultra purification of specialised biologics.
Veterinary Clinical Applications
Other than a blood transfusion, Oxy-Rx™ is an approved treatment that provides immediate relief from the clinical signs of canine anaemia.
Transforming intangible ideas into innovative solutions
Our Mission
Our mission is to provide for an unmet medical need and to present dramatic simple "solutions" for the healthcare providers and emergency first responders with a breakthrough product for Life-Sustaining Support of oxygen local (tissue, organ) and systemic (body) oxygen deprivation.
Our Goal & Unmet Need
We believe Oxy-Rx™ can meet the unmet need for safe / convenient / available oxygen perfusion agents to prevent poor outcomes and death due to a lack of tissue oxygen delivery (no blood cells and no flow) in the variety of situations and conditions.
Our Technology
This technology and the Modular Technology Platform will resolve a worldwide unmet medical need and allow safety, availability, and advanced medical care for every medical institution without the need for expanding blood banking costs and infrastructure.
Development Pipeline
What makes OXY-Rx™ different.
01. Unique Approach
OXY-Rx ™ is unique in its approach to formulation due to its extensive development history.
02. Unique Formulation
There are no similar platforms commercialised or under development. There are, however, investigative materials of a similar class under development.
03. Compliance
OXY-Rx™ is seen as the closest to market launch: 2023-2024; commercial and approvable.
For further information on OXY-Rx™ please contact us.
We would be happy to discuss it further.
0207 034 3300
We’d like to hear from you
Fitzrovia Hospital,
13-14 Fitzroy Square London, W1T 6AH
Please write to us
About
Markets
Press Releases
Contact